leisure time -WSS

leisure time

author：focus 2025-09-29 01:38:18 - browse：8

A new asthma treatment that could be administered just once every six months has succeeded in two Phase 3 trials, developer GlaxoSmithKline announced Tuesday.

The drug, depemokimab, is designed to treat asthma by targeting a protein called interleukin-5, or IL-5. The protein is linked to the type of inflammation found in most severe asthma cases, according to the pharma company.

Depemokimab hit its primary endpoints in the trials, reducing asthma attacks over a year’s time frame. The company didn’t disclose exact details from the SWIFT-1 and SWIFT-2 trials.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Virginia high school admissions case could be legal follow
Next article： Gene therapy for Afghan refugees’ infant will be fully covered

focus

WSS

Roche to buy Carmot Therapeutics, developer of obesity drugs

Gritstone Bio's cancer vaccine test, and more on Novartis' deal

Chemotherapy shortages won’t get better under Biden’s latest plan

Medicare Advantage plans can’t deny care with AI, CMS warns

Vyjuvek, a gene therapy for skin wounds, restored vision in one boy

Why CTE doesn’t keep Americans from enjoying the Super Bowl

focus

leisure time

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

knowledge

Hepatitis C has a cure — but many Americans still lack access to it

What’s missing from the debate over nursing home staff minimums

Virginia high school admissions case could be legal follow

并且说，他打算好好生活，努力把欠的钱还上。

ChatGPT in medicine: STAT answers readers' burning questions

Americans' trust in science, scientist continues decline: Report

Hepatitis C has a cure — but many Americans still lack access to it

STAT letters to the editor on burnt

Duchenne breakthrough therapy leaves behind pioneering families

What causes an itch? Researchers may have solved the mystery

focus

Top private equity targets in 2023: cardiology, clinical trials, lasers

After sickle

Readout LOUD: Venture capital, Gilead, and more M&A

Padmanee Sharma of MD Anderson at center of lawsuit over credit

Vyjuvek, a gene therapy for skin wounds, restored vision in one boy

Novo Holdings to buy drug manufacturer Catalent in $16.5B deal

hotspot

focus

focus

explore